EWP
VRTX icon

Elevation Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Elevation Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3K Buy
55
+28
+104% +$12.4K 0.01% 485
2026
Q1 		$12.1K Buy
27
+1
+4% +$466 ﹤0.01% 472
2025
Q4 		$11.8K Buy
26
+13
+100% +$5.6K ﹤0.01% 458
2025
Q3 		$5.09K Buy
+13
New +$5.43K ﹤0.01% 478
2025
Q1 		– Sell
-94
Closed -$37.9K – 515
2024
Q4 		$37.9K Hold
94
– – 0.02% 258
2024
Q3 		$43.7K Hold
94
– – 0.02% 232
2024
Q2 		$44.1K Hold
94
– – 0.02% 225
2024
Q1 		$39.3K Buy
+94
New +$39.7K 0.02% 237

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

Elevation Wealth Partners's VRTX Position: Q2 2026 in Review

Elevation Wealth Partners increased its Vertex Pharmaceuticals (VRTX) stake by 104% in Q2 2026, buying an estimated $12.4K and bringing the position to 55 shares worth $27.3K. The position accounts for 0.01% of the portfolio, ranked #485.

Elevation Wealth Partners first reported a position in VRTX in Q1 2024 and has held it in 8 quarters since. The position peaked at $44.1K in Q2 2024. 252 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Elevation Wealth Partners held 55 shares of Vertex Pharmaceuticals worth $27.3K as of Q2 2026.
  • Elevation Wealth Partners bought 28 Vertex Pharmaceuticals shares in Q2 2026, an estimated $12.4K.
  • Vertex Pharmaceuticals made up 0.01% of Elevation Wealth Partners's portfolio in Q2 2026, its #485 holding.
  • Elevation Wealth Partners first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
  • Elevation Wealth Partners's Vertex Pharmaceuticals position peaked at $44.1K in Q2 2024.
  • 252 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.